

Special Issue

SARS-CoV-2 Serological Studies around the Globe

Message from the Guest Editors

A novel coronavirus (2019-nCoV) associated with human to human transmission and severe human infection has been recently reported. Given the high transmissibility and the extensive geographic dispersal of the virus as well as the absence of effective treatments or a vaccine, public health measures provide the only way to prevent SARS-CoV-2 transmission. Given that SARS-CoV-2 is a new virus, we need to better understand the levels and the duration of protective immunity in patients with different severities of the disease (i.e., asymptomatic, mild and severe symptoms, hospitalized patients, ARDS symptoms), the levels of exposure to SARS-CoV-2 in highly vulnerable people and populations of special interest (i.e., healthcare workers, migrants, intravenous drug users, populations with limited access to health care facilities, HIV/AIDS patients), the parameters associated with the presence of antibodies, as well as the estimated performance of antibody testing in panels with known SARS-CoV-2 status. All of this information will be valuable across different geographic areas and different time periods.

Guest Editors

Prof. Dr. Angelos Hatzakis

1. Department of Hygiene, Epidemiology and Medical Statistics, Medical School, National and Kapodistrian University of Athens, 11527 Athens, Greece
2. Hellenic Scientific Society for the Study of AIDS, Sexually Transmitted and Emerging Diseases, 11527 Athens, Greece

Prof. Dr. Dimitrios Paraskevis

Department of Hygiene, Epidemiology and Medical Statistics, School of Medicine, National and Kapodistrian University of Athens, 115 27 Athens, Greece

Deadline for manuscript submissions

closed (31 May 2021)



Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4

CiteScore 9.9

Indexed in PubMed



mdpi.com/si/56233

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](http://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



[mdpi.com/journal/
vaccines](http://mdpi.com/journal/vaccines)

About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /
CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.1 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2025).

